| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Joseph W Iii Marshall | 3,656 | Grant/award etc. | $0.00 | |
| 4th January 2021 | Joseph W Iii Marshall | 4,128 | Grant/award etc. | $0.00 | |
| 27th August 2020 | James Antal | 30,000 | Open or private sale | $7.10 | $213,000.00 |
| 12th August 2020 | Eric A Md Rose | 661 | Grant/award etc. | $0.00 | |
| 7th August 2020 | Eric A Md Rose | 422 | Payment by withholding | $314.98 | $132,921.56 |
| 31st July 2020 | Robin Elizabeth Abrams | 14,138 | Payment by withholding | $6.42 | $90,765.96 |
| 31st July 2020 | Robin Elizabeth Abrams | 26,667 | Exercise of derivative | $0.00 | |
| 31st July 2020 | Daniel J Luckshire | 13,005 | Payment by withholding | $6.42 | $83,492.10 |
| 31st July 2020 | Daniel J Luckshire | 26,667 | Exercise of derivative | $0.00 | |
| 21st May 2020 | Jeffrey B Kindler | 15,000 | Exercise of derivative | $0.00 |
Siga Technologies
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.
Ticker: SIGA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1010086
Employees: 41
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $53 M (0%)
Inventory, Net: $14 M (0%)
Assets, Current: $105 M (-41%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $902 Th (5%)
Assets: $120 M (-39%)
Accounts Payable, Current: $630 Th (-79%)
Accrued Liabilities, Current: $15 M (0%)
Liabilities, Current: $16 M (-83%)
Liabilities: $26 M (-73%)
Common Stock, Value, Issued: $8 Th (-3%)
Common Stock, Shares, Issued: $79 M (-3%)
Additional Paid in Capital, Common Stock: $221 M (0%)
Retained Earnings (Accumulated Deficit): $127 M (3%)
Stockholders' Equity (Parent): $94 M (0%)
Liabilities and Equity: $120 M (-39%)
Revenue: $40 M (-6%)
Cost of Revenue: $5 M (-2%)
Research and Development: $3 M (-53%)
Operating Income/Loss: $29 M (16%)
Other Income, net: $32 Th (-92%)
Income before taxes: $27 M (74%)
Provision for income taxes: $6 M (0%)
EPS (basic): $0.26 (0%)
EPS (diluted): $0.26 (0%)
